Details for New Drug Application (NDA): 020326
✉ Email this page to a colleague
The generic ingredient in NEUTREXIN is trimetrexate glucuronate. There is one drug master file entry for this compound. Additional details are available on the trimetrexate glucuronate profile page.
Summary for 020326
Tradename: | NEUTREXIN |
Applicant: | Medimmune Oncology |
Ingredient: | trimetrexate glucuronate |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020326
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 25MG BASE/VIAL | ||||
Approval Date: | Dec 17, 1993 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 200MG BASE/VIAL | ||||
Approval Date: | Jul 31, 1998 | TE: | RLD: | No |
Expired US Patents for NDA 020326
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | 4,376,858 | ⤷ Subscribe |
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | 6,017,922 | ⤷ Subscribe |
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | 4,694,007 | ⤷ Subscribe |
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | 6,017,922 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription